Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Biodesix, Inc.NASDAQ: BDSX

Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other non-current liabilities rises 24.3% from a year ago

Other non-current liabilities stood at $860K at the end of Q1 FY2026, up 24.3% from a year earlier and down 15.8% from the prior quarter. Over 3 fiscal years it compounded at -62.4% a year.

Context

  • Other non-current liabilities amounted to 0.9% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
  • Other non-current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +24.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$860K-15.8% QoQ
Last fiscal yearDec 2025
$1.02M+25.3% YoY
Year agoMar 2025
$692K+24.3% since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.3%——
1 year+25.3%——
3-year CAGR-62.4%——
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
1.02M USD
Year-over-year change
+25.3%
4-year CAGR
-50.8%

Other Non-current Liabilities vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's Mar 2026 other non-current liabilities of $860K is the 2nd highest of the 5 companies compared; the peer median is $6K.
  • Its year-over-year change of +24.3% is the highest of 2, against a peer median of -70.0%.
  • Other non-current liabilities amounts to 0.9% of total assets for BDSX, versus a peer median of 0.0%.
BDSX Competitors Peer median
Other Non-current Liabilities for BDSX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XLOXilio Therapeutics, Inc.Mar 2026$42.73M —+985.3%26.1%
BDSXBiodesix, Inc.Mar 2026$860K +24.3%-62.4%0.9%
OKUROnKure Therapeutics, Inc.Mar 2026$12K -70.0%-94.3%0.0%
PDSBPDS Biotechnology CorporationMar 2026$0 ——0.0%
INMBINmune Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding BDSX) $6K-70.0%+445.5%0.0%

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents32.71M43.09M26.28M26.25M18.99M
Short-term Investments00000
Net Receivables3.66M5.07M7.68M8.6M9.04M
Inventory2.9M1.4M1.4M00
Other Current Assets7.25M5.18M4.32M4.64M4.5M
Total Current Assets43.61M53.33M39.68M39.48M32.52M
Property, Plant & Equipment (Net)4.18M8.82M29.61M29.6M27.81M
Goodwill15.03M15.03M15.03M15.03M15.03M
Intangible Assets11.62M9.8M7.91M5.87M3.88M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.66M5.92M6.86M7.26M8.23M
Total Non-current Assets32.48M39.57M59.41M57.76M54.96M
Total Assets76.1M92.91M99.1M97.24M87.48M
Account Payables1.66M1.69M2.93M2.19M3.08M
Short-term Debt19K49K51K21K6K
Tax Payables00000
Deferred Revenue1.85M962K324K678K961K
Other Current Liabilities21.4M15.05M26.01M792K8.83M
Total Current Liabilities28.96M22.84M33.42M14.32M17.44M
Long-term Debt9.99M25M35.23M36.41M47.45M
Deferred Tax Liabilities0(400K)000
Deferred Revenue (Non-current)0400K000
Other Non-current Liabilities17.42M19.2M712K815K1.02M
Total Non-current Liabilities27.41M49.46M61.1M62.05M72.51M
Total Liabilities56.37M72.3M94.52M76.37M89.94M
Common Stock31K78K96K145K8K
Retained Earnings(301.97M)(367.42M)(419.57M)(462.5M)(497.76M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity19.73M20.61M4.58M20.88M(2.47M)
Total Debt10.01M31.85M60.69M61.98M72.85M
Net Debt(22.7M)(11.24M)34.41M35.73M53.87M

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.